Cargando…

Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review

Erlotinib is among the oral EGFR-tyrosine kinase inhibitors used to treat non-small cell lung cancer. The common side effects of erlotinib include acne form rash and diarrhea. Eyelash trichomegaly and alterations of scalp hair are rarely observed symptoms. In the present study, we report changes in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Hua, Zhang, Hongmei, Zhang, Tongmei, Wang, Qunhui, Hu, Fanbin, Li, Baolan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998076/
https://www.ncbi.nlm.nih.gov/pubmed/27588051
http://dx.doi.org/10.3892/etm.2016.3460
_version_ 1782449878209658880
author Zheng, Hua
Zhang, Hongmei
Zhang, Tongmei
Wang, Qunhui
Hu, Fanbin
Li, Baolan
author_facet Zheng, Hua
Zhang, Hongmei
Zhang, Tongmei
Wang, Qunhui
Hu, Fanbin
Li, Baolan
author_sort Zheng, Hua
collection PubMed
description Erlotinib is among the oral EGFR-tyrosine kinase inhibitors used to treat non-small cell lung cancer. The common side effects of erlotinib include acne form rash and diarrhea. Eyelash trichomegaly and alterations of scalp hair are rarely observed symptoms. In the present study, we report changes in eyelash trichomegaly and scalp hair in six cases of pulmonary adenocarcinoma patients that had been administered erlotinib. The symptoms of eyelash trichomegaly include curly, irregular, excessively long and brittle eyelashes, and alterations of scalp hair include curly or straight, brittle, fine or rigid, reduced growth rate and volume. Since these side effects does not substantially impact patient quality of life, no treatments were administered. These changes in eyelashes and scalp hair gradually disappeared after withdrawal of erlotinib.
format Online
Article
Text
id pubmed-4998076
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-49980762016-09-01 Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review Zheng, Hua Zhang, Hongmei Zhang, Tongmei Wang, Qunhui Hu, Fanbin Li, Baolan Exp Ther Med Articles Erlotinib is among the oral EGFR-tyrosine kinase inhibitors used to treat non-small cell lung cancer. The common side effects of erlotinib include acne form rash and diarrhea. Eyelash trichomegaly and alterations of scalp hair are rarely observed symptoms. In the present study, we report changes in eyelash trichomegaly and scalp hair in six cases of pulmonary adenocarcinoma patients that had been administered erlotinib. The symptoms of eyelash trichomegaly include curly, irregular, excessively long and brittle eyelashes, and alterations of scalp hair include curly or straight, brittle, fine or rigid, reduced growth rate and volume. Since these side effects does not substantially impact patient quality of life, no treatments were administered. These changes in eyelashes and scalp hair gradually disappeared after withdrawal of erlotinib. D.A. Spandidos 2016-09 2016-06-16 /pmc/articles/PMC4998076/ /pubmed/27588051 http://dx.doi.org/10.3892/etm.2016.3460 Text en Copyright: © Zheng et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Zheng, Hua
Zhang, Hongmei
Zhang, Tongmei
Wang, Qunhui
Hu, Fanbin
Li, Baolan
Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
title Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
title_full Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
title_fullStr Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
title_full_unstemmed Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
title_short Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
title_sort trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: a case report and literature review
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998076/
https://www.ncbi.nlm.nih.gov/pubmed/27588051
http://dx.doi.org/10.3892/etm.2016.3460
work_keys_str_mv AT zhenghua trichomegalyandscalphairchangesfollowingtreatmentwitherlotinibinpulmonaryadenocarcinomapatientsacasereportandliteraturereview
AT zhanghongmei trichomegalyandscalphairchangesfollowingtreatmentwitherlotinibinpulmonaryadenocarcinomapatientsacasereportandliteraturereview
AT zhangtongmei trichomegalyandscalphairchangesfollowingtreatmentwitherlotinibinpulmonaryadenocarcinomapatientsacasereportandliteraturereview
AT wangqunhui trichomegalyandscalphairchangesfollowingtreatmentwitherlotinibinpulmonaryadenocarcinomapatientsacasereportandliteraturereview
AT hufanbin trichomegalyandscalphairchangesfollowingtreatmentwitherlotinibinpulmonaryadenocarcinomapatientsacasereportandliteraturereview
AT libaolan trichomegalyandscalphairchangesfollowingtreatmentwitherlotinibinpulmonaryadenocarcinomapatientsacasereportandliteraturereview